GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Cyclically Adjusted PB Ratio

HLTRF (HLS Therapeutics) Cyclically Adjusted PB Ratio : 0.75 (As of Jun. 01, 2025)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-06-01), HLS Therapeutics's current share price is $3.22. HLS Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $4.31. HLS Therapeutics's Cyclically Adjusted PB Ratio for today is 0.75.

The historical rank and industry rank for HLS Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

HLTRF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.51   Med: 1.41   Max: 6.48
Current: 0.8

During the past years, HLS Therapeutics's highest Cyclically Adjusted PB Ratio was 6.48. The lowest was 0.51. And the median was 1.41.

HLTRF's Cyclically Adjusted PB Ratio is ranked better than
78.1% of 694 companies
in the Drug Manufacturers industry
Industry Median: 1.94 vs HLTRF: 0.80

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

HLS Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $2.105. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.31 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


HLS Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for HLS Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Cyclically Adjusted PB Ratio Chart

HLS Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.19 3.03 1.76 0.66 0.64

HLS Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.55 0.62 0.64 0.75

Competitive Comparison of HLS Therapeutics's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

HLS Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

HLS Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.22/4.31
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, HLS Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.105/129.1809*129.1809
=2.105

Current CPI (Mar. 2025) = 129.1809.

HLS Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 2.186 100.500 2.810
201509 2.015 100.421 2.592
201512 1.924 99.947 2.487
201603 2.039 101.054 2.607
201606 2.029 102.002 2.570
201609 1.989 101.765 2.525
201612 1.924 101.449 2.450
201703 1.918 102.634 2.414
201706 1.948 103.029 2.442
201709 2.018 103.345 2.523
201712 6.576 103.345 8.220
201803 6.916 105.004 8.508
201806 6.735 105.557 8.242
201809 6.113 105.636 7.476
201812 5.807 105.399 7.117
201903 5.750 106.979 6.943
201906 6.281 107.690 7.534
201909 6.133 107.611 7.362
201912 5.737 107.769 6.877
202003 5.297 107.927 6.340
202006 5.311 108.401 6.329
202009 5.319 108.164 6.352
202012 5.319 108.559 6.329
202103 5.262 110.298 6.163
202106 5.267 111.720 6.090
202109 5.079 112.905 5.811
202112 4.953 113.774 5.624
202203 4.898 117.646 5.378
202206 4.455 120.806 4.764
202209 4.056 120.648 4.343
202212 3.873 120.964 4.136
202303 3.675 122.702 3.869
202306 3.450 124.203 3.588
202309 3.166 125.230 3.266
202312 3.055 125.072 3.155
202403 2.793 126.258 2.858
202406 2.601 127.522 2.635
202409 2.495 127.285 2.532
202412 2.244 127.364 2.276
202503 2.105 129.181 2.105

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


HLS Therapeutics  (OTCPK:HLTRF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


HLS Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.